Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2003-10-28
2010-06-08
Ewoldt, G. R (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100, C530S387900
Reexamination Certificate
active
07731964
ABSTRACT:
The invention discloses newly-discovered phosphorylation sites in human IRS-1 and IRS-2, serine 1101 (Ser1101) and serine 1149 (Ser1149) respectively, and provides antibodies, both polyclonal and monoclonal, that selectively bind to IRS-1 and/or IRS-2 when phosphorylated at these respective sites, but do not bind to IRS-1 and/or IRS-2 when not phosphorylated at these respective sites. The sites are relevant to insulin-resistance in type 2 diabetes. Also provided are methods for determining the phosphorylation of IRS-1/2 or activity of PKC theta in a biological sample, by using a detectable reagent, such as the disclosed antibodies, that binds to IRS-1/2 only when phosphorylated at Ser1101/Ser1149. Kits comprising the phosphor-IRS-1/2 (Ser1101/1149) antibodies of the invention are also provided.
REFERENCES:
patent: 4208479 (1980-06-01), Zuk et al.
patent: 5593678 (1997-01-01), Evans et al.
patent: 5621075 (1997-04-01), Kahn et al.
patent: 5807702 (1998-09-01), Mukerji et al.
Sigma Chemical Co. 1998; p. 1308.
Saltiel et al.,Nature414: 799-806 (2001).
White, M.F.,Mol. Cell. Biochem. 182: 3-11 (1998).
Holgado-Madruga et al.,Nature379: 560-564 (1996).
Moodie et al.,J. Biol. Chem.. 274: 11186-11193 (1999).
Saltiel et al.,Trends Cell Bio. 12: 65-71 (2002).
Zick Y.,Trends Cell bio. 11: 437-441 (2001).
Jiang et al.,Diabetes48: 1120-1130 (1999).
Mothe et al.,J. Biol. Chem. 271: 9351-9356 (1996).
Li J.,J. Biol. Chem. 274: 9351-9356 (1999).
Aguirre et al. J. Biol. Chem. 275: 9047-9054 (2000).
Rui et al.,J. Clin. Invest. 107: 181-189 (2001).
Aguirre et al.,J. Biol. Chem. 277: 1531-1537 (2002).
Griffin et al.,Diabetes48: 1270-1274 (1999).
Itani et al.,Metabolism50: 553-557 (2001).
Qu et al.,J. Endocrinol. 162: 207-214 (1999).
Chalfant et al.,Endocrinology141: 2773-2778 (2000).
Solow, et al.,Molecular Endocrinology, vol. 13 No. 10, pp. 1784-1798 (1999).
Li Yu
Polakiewicz Roberto
Wu Jiong
Cell Signaling Technology, Inc.
CST Legal Dept.
Ewoldt G. R
LandOfFree
Antibodies specific for phosphorylated insulin receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies specific for phosphorylated insulin receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies specific for phosphorylated insulin receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186398